solitude72/iStock via Getty Images Johnson & Johnson ( JNJ ) has transferred ownership to Vanda Pharmaceuticals ( NASDAQ: VNDA ) of the FDA new drug and investigational drug applications for the multiple sclerosis drug Ponvory, also known as ponesimod. Vanda acquired the US and Canadian rights to the therapy in December from J&J’s Actelion unit. The drug is approved in the US and Canada for the treatment of relapsing forms of multiple sclerosis, or RMS.
Vanda plans to launch Ponvory RMS in Q3. More on Vanda Pharmaceuticals Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals rejects sweetened bid from Future Pak Vanda reports positive Phase 3 data for motion sickness drug Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals.
